SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy
This pilot clinical trial studies single photon emission computed tomography (SPECT)/computed tomography (CT) in measuring lung function in patients with cancer undergoing radiation therapy. Diagnostic procedures that measure lung function may help doctors find healthy lung tissue and allow them to plan better treatment.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 2 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 13, 2018 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Washington
- Interventions being studied
- Diagnostic Test: SPECT/CT; Procedure: Single Photon Emission Computed Tomography; Radiation: Technetium Tc-99m Albumin Aggregated; Drug: Technetium Tc-99m DTPA
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Cancer patients receiving radiation treatment to the thorax to at least 45 Gy; patient must have pathologic confirmation of diagnosis, or have an enlarging lung mass on at least two scans spaced 3 months apart, and FDG avidity on PET scan
- Patients must be planned for at least 45 Gy of thoracic radiation
- Patients are not required to have measurable disease; post-operative patients (patients who have had surgical resection of the lung) are eligible
- Patients must have pulmonary function as defined below:
- Abnormal pulmonary function test within 3 months of study entry
- Prior radiation to the lungs
- Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy)
- Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema
- Ongoing oxygen use
- There are no limits on prior therapy; patients are allowed to have prior chemotherapy, radiation therapy, and surgery; patients are allowed to have concurrent chemotherapy with radiation treatment; patients are allowed to have chemotherapy after radiation treatment; patients are not allowed to have planned lung resection after radiation
- Ability to understand and the willingness to sign a written informed consent document
- Patients will typically be enrolled on this trial prior to beginning the radiation treatment course; however, if a patient has had a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan as part of routine medical care within 6 weeks prior to initiation of radiation treatment, he/she is eligible for trial enrollment up to the last day of the radiation treatment course
- Patients must not be planned for lung resection after radiation therapy
- Patients receiving \< 45 Gy radiation
- Patients who received radiation to the chest within the past 6 months
- Patients unable to tolerate a SPECT/CT 99mTc-MAA and 99mTc-DTPA scan
- Patients who are not planning to adhere to the required follow up schedule as outlined in this protocol
- Pregnant women
- Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- Patients unable to provide informed consent
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumSeattle, Washington
- ProCure Proton Therapy Center-SeattleSeattle, Washington
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 13, 2018. Always confirm current availability with the study team.